Pfizer cuts neuroscience meds from pipeline

Pfizer also revealed that it spent $1.7 billion in R&D in the first quarter.

Alongside its first-quarter financials today, Pfizer also sneaked in details of its “discontinued projects,” this year, which includes meds from its CV and metabolism pipeline and from its neuroscience unit.

The ax swung in the last few months for PF-06291874, a midstage med in testing for Type 2 diabetes; PF-06815345 for hyperlipidemia; and PF-06412562 for cognitive disorders, and PF-02545920, a PDE10 inhibitor in phase 2 for Huntington's disease saw the chop in the first quarter. 

Its diabetes med was a glucagon receptor antagonist, while its hyperlipidemia candidate was, according to its FY update last February, new in to its pipeline for phase 1 testing, but with precious few other details about its MOA. The same goes for PF-06412562, also a phase 1 candidate, in its neuroscience and pain unit.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The phase 2 Huntington's disease candidate, out of its neuroscience department, was a small molecule NME that had orphan status in the U.S. According to, the: "Study terminated on 15 Dec. 2016 due to study A8241021 showing no significant difference on primary endpoint between PF-02545920 & placebo. No safety concerns."

In its financials, Pfizer also revealed that it spent $1.7 billion in R&D in the first quarter, a 1% decline on last year. 


Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.